Skip to main content

Ontario-led Team Receives $4.7M from Movember to Develop Dx to Guide Prostate Cancer Treatment

NEW YORK (GenomeWeb) – A research team led by scientists at the Ontario Institute for Cancer Research have received a C$5 million (US$4.7 million) grant from the Movember Foundation to develop diagnostic molecular markers that physicians could use to make treatment decisions for their prostate cancer patients.

Called PRONTO, the project was funded by a Movember Team Grant that was awarded by Prostate Cancer Canada, PCC said on Tuesday.

The effort will be led by Principal Investigator John Bartlett at OICR, in Toronto, but will involve 14 co-investigators at institutions in several other provinces.

"PCC's team of international reviewers identified the team research project that is poised to have the greatest impact in prostate cancer diagnosis, treatment, or prevention," PCC President and CEO Rocco Rossi said in a statement.

The PRONTO team wants to develop a diagnostic tool to address a serious issue facing doctors who treat prostate cancer; that PSA screening identifies many cases that pose no real threat over a man's lifetime and that many men are undergoing unnecessary radical prostatectomies and other treatments. The researchers plan to develop molecular diagnostic tests to better predict which men are likely to develop aggressive cancer and to develop personalized treatments for early cancers.

The multidisciplinary PRONTO research team includes pathologists, surgeons, oncologists, biostatisticians, and computational biologists. They plan to validate their test in a large group of men who were previously diagnosed with prostate cancer to confirm its accuracy and to accelerate it toward clinical use.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.